Rep. Norm Thurston — Voting Record

Bill

Number

H.B. 25 (2020GS)

Sponsor

Rep. Ray, P.

Final action

Governor Signed 3/24/2020

Outcome

Became law — signed by Gov. Gary R. Herbert

Summary

What it does

• This bill:
• adds a substance to the listed controlled substances in the Utah Controlled Substances Act;
• amends the composition of the Controlled Substances Advisory Committee; and
• makes technical changes.

Every vote on this bill

Bill text

CONTROLLED SUBSTANCES REVISIONS
GENERAL SESSION
STATE OF UTAH
Chief Sponsor: Paul Ray
Senate Sponsor: 
Allen M. Christensen
LONG TITLE
General Description:
This bill amends the list of controlled substances and the composition of the Controlled
Substances Advisory Committee.
Highlighted Provisions:
This bill:
▸ adds a substance to the listed controlled substances in the Utah Controlled
Substances Act;
▸ amends the composition of the Controlled Substances Advisory Committee; and
▸ makes technical changes.
Money Appropriated in this Bill:
None
Other Special Clauses:
None
Utah Code Sections Affected:
AMENDS:
58-37-4.2
, as last amended by Laws of Utah 2018, Chapter 146
58-38a-201
, as last amended by Laws of Utah 2011, Chapter 60
58-38a-202
, as last amended by Laws of Utah 2011, Chapter 60
Be it enacted by the Legislature of the state of Utah:
Section 1. Section 
58-37-4.2
 is amended to read:
58-37-4.2.
Listed controlled substances.
The following substances, their analogs, homologs, and synthetic equivalents are listed
controlled substances:
(1) AB-001;
(2) AB-PINACA;
N-[1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide;
(3) AB-FUBINACA; N-[1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)
methyl]-1H-indazole-3-carboxamide;
(4) AB-CHMINACA
(N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);
(5) ADB-CHMINACA (N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
(cyclohexylmethyl)indazole-3-carboxamide);
(6) ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1oxobutan-2-yl)-1-
(4-fluorobenzyl)-1H-indazole-3-caboxamide);
(7) AKB48;
(8) alpha-Pyrrolidinohexanophenone (alpha-PHP)
(1-Phenyl-2-(pyrrolidin-1-yl)hexan-1-one);
(9) alpha-Pyrrolidinovalerophenone (alpha-PVP);
(10) AM-694 (1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone);
(11) AM-1248;
(12) AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole);
(13) AM-2233;
(14) AM-679;
(15) A796,260;
(16) Butylone;
(17) CP 47,497 and its C6, C8, and C9 homologs (2-[(1R,3S)-3-hydroxycyclohexyl]
-5-(2-methyloctan-2-yl)phenol);
(18) Diisopropyltryptamine (DiPT);
(19) Ethylone;
(20) Ethylphenidate;
(21) Fluoroisocathinone;
(22) Fluoromethamphetamine;
(23) Fluoromethcathinone;
(24) FUB-AMB; methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)valinate;
(25) HU-210; (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
(26) HU-211; Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
(27) JWH-015; (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone;
(28) JWH-018; Naphthalen-1-yl-(pentylindol-3-yl)methanone {also known as
1-Pentyl-3-(1-naphthoyl)indole};
(29) JWH-019; 1-hexyl-3-(1-naphthoyl)indole;
(30) JWH-073; Naphthalen-1-yl(1-butylindol-3-yl)methanone {also known as
1-Butyl-3-(1-naphthoyl)indole};
(31) JWH-081; 4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone;
(32) JWH-122; CAS#619294-47-2; (1-Pentyl-3-(4-methyl-1-naphthoyl)indole);
(33) JWH-200; 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
(34) JWH-203; 1-pentyl-3-(2-chlorophenylacetyl)indole;
(35) JWH-210; 4-ethyl-1-naphthalenyl(1-pentyl-1H-indol-3-yl)-methanone;
(36) JWH-250; 1-pentyl-3-(2-methoxyphenylacetyl)indole;
(37) JWH-251; 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone;
(38) JWH-398; 1-pentyl-3-(4-chloro-1-naphthoyl)indole;
(39) MAM-2201;
(40) MAM-2201;
(1-(5-fluoropentyl)-1H-indol-3-yl)(4-ethyl-1-naphthalenyl)-methanone;
(41) Methoxetamine;
(42) Naphyrone;
(43) PB-22; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester;
(44) Pentedrone;
(45) Pentylone;
(46) RCS-4; 1-pentyl-3-(4-methoxybenzoyl)indole;
(47) RCS-8; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole {also known as
BTW-8 and SR-18};
(48) STS-135;
(49) UR-144;
(50) UR-144 N-(5-chloropentyl) analog;
(51) XLR11;
(52) 2C-C;
(53) 2C-D;
(54) 2C-E;
(55) 2C-H;
(56) 2C-I;
(57) 2C-N;
(58) 2C-P;
(59) 2C-T-2;
(60) 2C-T-4;
(61) 2NE1;
(62) 25I-NBOMe;
(63) 2,5-Dimethoxy-4-chloroamphetamine (DOC);
(64) 4-Fluoro MDMB-BUTINACA (Methyl
2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate);
[
(64)
] 
(65)
 4-methylmethcathinone {also known as mephedrone};
[
(65)
] 
(66)
 3,4-methylenedioxypyrovalerone {also known as MDPV};
[
(66)
] 
(67)
 3,4-Methylenedioxymethcathinone {also known as methylone};
[
(67)
] 
(68)
 4-methoxymethcathinone;
[
(68)
] 
(69)
 4-Methyl-alpha-pyrrolidinopropiophenone;
[
(69)
] 
(70)
 4-Methylethcathinone;
[
(70)
] 
(71)
 5F-AKB48;
1-(5-flouropentyl)-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3- carboxamide;
[
(71)
] 
(72)
 5-Fluoro ADB (Methyl
N-{[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl}-3-methyl-valinate);
[
(72)
] 
(73)
 5-Fluoro AMB (Methyl
N-{[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl}valinate);
[
(73)
] 
(74)
 5-fluoro-PB-22; 1-(5-fluoropentyl)-1H-indole-3-carboxylic acid
8-quinolinyl ester;
[
(74)
] 
(75)
 5-Iodo-2-aminoindane (5-IAI);
[
(75)
] 
(76)
 5-MeO-DALT;
[
(76)
] 
(77)
 25B-NBOMe; 2-(r-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
methyl]ethanamine;
[
(77)
] 
(78)
 25C-NBOMe; 2-(4Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
methyl]ethanamine; and
[
(78)
] 
(79)
 25H-NBOMe;
2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine.
Section 2. Section 
58-38a-201
 is amended to read:
58-38a-201.
Controlled Substances Advisory Committee.
There is created within the Division of Occupational and Professional Licensing the
Controlled Substances Advisory Committee. The committee consists of:
(1) the director of the Department of Health or the director's designee;
(2) the State Medical Examiner or the examiner's designee;
(3) the commissioner of the Department of Public Safety or the commissioner's
designee;
(4) the director of the Bureau of Forensic Services created in Section 
53-10-401
, or the
director's designee;
(5) the director of the Utah Poison Control Center or the director's designee;
[
(4)
] 
(6)
 one physician who is a member of the Physicians Licensing Board and is
designated by that board;
[
(5)
] 
(7)
 one pharmacist who is a member of the Utah State Board of Pharmacy and is
designated by that board;
[
(6)
] 
(8)
 one dentist who is a member of the Dentist and Dental Hygienist Licensing
Board and is designated by that board;
[
(7)
] 
(9)
 one physician who is currently licensed and practicing in the state, to be
appointed by the governor;
[
(8)
] 
(10)
 one psychiatrist who is currently licensed and practicing in the state, to be
appointed by the governor;
[
(9)
] 
(11)
 one individual with expertise in substance abuse addiction, to be appointed
by the governor;
[
(10)
] 
(12)
 one representative from the Statewide Association of Prosecutors, to be
designated by that association;
[
(11)
] 
(13)
 one naturopathic physician who is currently licensed and practicing in the
state, to be appointed by the governor;
[
(12)
] 
(14)
 one advanced practice registered nurse who is currently licensed and
practicing in this state, to be appointed by the governor; and
[
(13)
] 
(15)
 one member of the public, to be appointed by the governor.
Section 3. Section 
58-38a-202
 is amended to read:
58-38a-202.
Terms of committee service.
(1) (a) Members of the advisory committee shall serve terms of four years, except that
the members under Subsections 
58-38a-201
(1), (2), [
and
] (3)
, and (4)
 shall serve during their
terms as appointed officials.
(b) Vacancies in the committee occurring otherwise than by the expiration of a term
shall be filled for the unexpired term in the same manner as original appointments.
(2) A member may not receive compensation or benefits for the member's service, but
may receive per diem and travel expenses in accordance with:
(a) Section 
63A-3-106
;
(b) Section 
63A-3-107
; and
(c) rules made by the Division of Finance pursuant to Sections 
63A-3-106
 and
63A-3-107
.
(3) (a) The director of the Department of Health, or the director's designee, is the chair
of the committee.
(b) The advisory committee meets at the call of the chair or at the call of a majority of
the committee members.
(c) The advisory committee meets annually and more often as required to carry out its
duties under this chapter.
(d) Seven members of the advisory committee constitute a quorum.
(e) Action by the committee requires a majority vote of a quorum.